WiseGuyRerports.com Presents “Global Thyroid Disorder Market Research Report Forecast to 2022” New Document to its Studies Database
Thyroid disorders result from elevated or decreased secretions of the hormones by the thyroid gland. According to research studies published by the National Institute for Health and Care Excellence published in 2017, hypothyroidism was found in 27.2% of the total UK population. This report analyses the current status of the global thyroid disorder market, outlines the key market drivers and the bases for market segmentation and studies the trends of this market till 2022.
The global thyroid disorder market is estimated to reach USD 2,914.93 million by 2022 from USD 2,442.47 million in 2017 at a CAGR of 3.60%. According to studies conducted by the American Thyroid Association, over 12% of the U.S. population is prone to thyroid disorders once in their lifetime with women being more susceptible to thyroid disease than men. The rising prevalence of thyroid diseases, growing awareness of the disease, favourable healthcare policies and funding by the governments of nations across the world, are boosting the growth of the thyroid disorder market.
According to some recent studies as of July 2019, as more people in India are being diagnosed with thyroid disease, experts warn that thyroid disorder may be the new diabetes. According to international research on thyroid disease, millions of people in the UK are being prescribed thyroid drugs unnecessarily. Most patients with hypothyroidism were prescribed daily lifelong pills, which according to experts may not benefit for all patients with mild or sub clinical hypothyroidism.
Pfizer Inc, Allergan, AbbVie Inc., Merck KGaA, RLC Labs, GlaxoSmithKline Plc, and Mylan
The global thyroid disorder market has been segmented based on type, treatment, method of administration, end user, and geographical region.
On the basis of type, the global thyroid disorder market has been split into hypothyroidism and hyperthyroidism. Of these, hypothyroidism holds the higher share of the market.
Based on treatment, this market can be split into medications, radioactive iodine therapy, and surgery. It is predicted that the medications segment will grow at a CAGR of 3.71% from 2018 to 2022.
According to the method of administration of treatment, the global thyroid disorder market has been segmented into oral, intravenous, and others. Of these, the oral segment is preferred widely owing to its high effectiveness and easy availability.
Finally, on the basis of end user, this market can be divided into hospitals, clinics, and others. Of these, the hospitals segment is expected to grow at a CAGR of 3.89% over the forecast period to reach a value of USD 1,361.31 million.
North America, Europe, Asia-Pacific, South America, and Middle East and Africa are the major regions for thyroid disorder market across the world.
While America is expected to hold the major share of the global thyroid disorder market, with a growth rate of 3.50% from 2018 to 2022, followed by Europe, it is believed that the Asia-Pacific region will be the fastest growing market, registering a CAGR of 4.01% from 2018 to 2022. This could be due to the expansion of the markets in developing economies such as India and China.
To raise awareness in the medical fraternity and the general public, two medical associations — the ITS (Indian Thyroid Society) and the FOGSI (the Federation of Obstetric and Gynaecological Societies of India), have tied up with multinational healthcare company Abbott to launch the ‘Making India Thyroid Aware’ campaign.
Table Of Content:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
Chapter 6. Global By Type
Chapter 7. Global By Treatment
Chapter 8. Global By End Users
Chapter 9. Global By Region
Chapter 10. Company Landscape
Chapter 11 Company Profiles
Chapter 12 MRFR Conclusion
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)